ClearPoint Neuro CEO Joseph Burnett sells shares worth $282k

Published 12/06/2025, 02:56
ClearPoint Neuro CEO Joseph Burnett sells shares worth $282k

Joseph Burnett, CEO and President of ClearPoint Neuro, Inc. (NASDAQ:CLPT), recently sold 21,247 shares of the company’s common stock. The shares were sold at an average price of $13.29, resulting in a total transaction value of approximately $282,372. The transaction comes as CLPT shows impressive momentum, with the stock delivering a 127% return over the past year according to InvestingPro data. Following this transaction, Burnett holds 243,522 shares indirectly through the Joseph M. Burnett Trust. The sale was part of a net share settlement related to a restricted stock unit that vested earlier this year. With a market capitalization of $363 million and analyst price targets ranging from $28-30, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report that provides detailed analysis of CLPT’s financial health and growth prospects.

In other recent news, ClearPoint Neuro Inc. reported first-quarter 2025 revenue of $8.5 million, exceeding analyst forecasts by 3.16%. This figure marks an 11% increase compared to the same period last year, driven largely by a 70% growth in the Neurosurgery Navigation segment. However, the company noted a significant 63% decrease in Capital Equipment and Software (ETR:SOWGn) revenue, highlighting areas that may require attention. ClearPoint Neuro’s operational cash burn increased by $2.3 million, raising potential concerns about financial resource management. The company has also secured new funding from Overland Capital, providing flexibility for future strategic initiatives. ClearPoint Neuro plans to activate 15 to 20 new sites this year and is pursuing GLP certification, which could enhance its commercial capabilities. In terms of analyst activity, Lake Street Capital Markets and B. Riley Securities have shown interest in the company’s strategic direction and recent financing efforts. These developments reflect ClearPoint Neuro’s ongoing efforts to expand its market presence and innovate within the neurosurgery field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.